Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis.
about
Differences in the effects of extended-release aspirin and plain-formulated aspirin on prostanoids and nitric oxide in healthy volunteersDrug delivery and therapeutic impact of extended-release acetylsalicylic acid.Safety and tolerability of extended-release acetylsalicylic acid capsules: a summary of double-blind comparative studies.Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events.Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium.
P2860
Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Comparison of antiplatelet act ...... patients with atherosclerosis.
@ast
Comparison of antiplatelet act ...... patients with atherosclerosis.
@en
type
label
Comparison of antiplatelet act ...... patients with atherosclerosis.
@ast
Comparison of antiplatelet act ...... patients with atherosclerosis.
@en
prefLabel
Comparison of antiplatelet act ...... patients with atherosclerosis.
@ast
Comparison of antiplatelet act ...... patients with atherosclerosis.
@en
P2093
P2860
P1476
Comparison of antiplatelet act ...... patients with atherosclerosis.
@en
P2093
Heptinstall S
P2860
P356
10.1046/J.1365-2125.1999.00947.X
P407
P577
1999-07-01T00:00:00Z